晚期NSCLC靶向和化疗方案选择的几个问题

ccxmo · 发表于 2013-4-29 07:39:39

安安康康发表于 2013-4-24 22:27

登录/注册后可看大图

马哥辛苦了，是不是靶向、化疗也对kras突变有影响呀。妈妈易瑞沙耐药（十一个月）后，用血浆重新检测egfr、 ...

那你后续准备如何控制？

安安康康 · 发表于 2013-4-29 13:26:27

ccxmo 发表于 2013-4-29 07:39

登录/注册后可看大图

那你后续准备如何控制？

现在吃着多吉美

与妻共舞 · 发表于 2013-5-1 00:51:17

提示: 作者被禁止或删除内容自动屏蔽

与妻共舞 · 发表于 2013-5-1 00:52:39

提示: 作者被禁止或删除内容自动屏蔽

dd163 · 发表于 2013-5-2 15:52:54

phpinfo 发表于 2013-4-28 23:01

登录/注册后可看大图

按照老马的说话，缓慢进展可以维持原来的靶向+单药的化疗
我前一阵问诊过几个比较知名的大夫，也都是倾向 ...

用原来的还是要耐药啊，最好的是换靶向，换有效率比较高点的靶向。祝你家有效，好运！

becool36 · 发表于 2013-5-9 02:34:57

真是总结的太好了。。

定江定海 · 发表于 2013-5-24 15:55:18

mark 学习

yiyiyi330 · 发表于 2013-5-24 19:53:20

学习中......多谢老马的帖子，辛苦了！

niunaibaolanse · 发表于 2013-5-24 20:14:21

克里唑蒂尼现在在国内没有卖吧

老马 · 发表于 2013-5-27 02:25:41

Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation.
http://www.ncbi.nlm.nih.gov/pubmed/23493804
A 72-year-old woman was referred to our hospital with Stage IV non-small-cell lung cancer (NSCLC). Chest computed tomography revealed a mass in the upper lobe of the right lung, with pleural effusion. Cytologic examination identified adenocarcinoma cells in the right pleural effusion. Furthermore, both a deletion mutation in exon 19 and a threonine-methionine substitution mutation at position 790 in exon 20 (T790M) were detected in the epidermal growth factor receptors (EGFR) in the malignant cells. As systemic chemotherapy consisting of carboplatin and pemetrexed or erlotinib proved ineffective, docetaxel monotherapy was initiated as a third-line treatment. Following salvage chemotherapy, her Eastern Cooperative Oncology Group performance status improved from 3 to 1, with tumor regression over 5 months. To the best of our knowledge, this is the first report of successful docetaxel treatment for a patient with NSCLC harboring the T790M EGFR-activating mutation identified before treatment with EGFR tyrosine kinase inhibitors.